XRTX: XORTX Corp Price to Sales

Corporate company logo of XORTX Corp (XRTX)

XORTX Therapeutics Inc. (XRTX) is developing targeted therapies to combat cardiovascular and renal pathologies. The company is mitigating risks by creating therapy to lower uric acid during metabolic disruptions. The current strategic focus is directed toward scaling treatment programs for polycystic kidney disease and identifying biopharma partners. Monitoring the company's P/S ratio visualizes the market valuation of sales, where determines this parameter level.

XRTX (XORTX) Price-to-Revenue Ratio history from 07/04/2022 to 11/16/2026

XORTX (XRTX) - metric breakdowns and financial figures

- stock price and consensus target price:
Summary company analytics:XORTX (XRTX)
Finished products of XORTX Therapeutics Inc

The P/S multiple compares the market capitalization of XORTX Therapeutics Inc. (XRTX) with its annual sales volume, determining the cost of each unit of revenue to assess whether the asset is overbought. When analyzing the price-to-sales history, it is critical to consider the biotech ecosystem's lack of a commercial base and its dependence on FDA decisions, which transforms this indicator into a marker of speculative investor expectations regarding future orphan statuses.

Who XORTX Therapeutics Inc. competes with

argenx - Market Cap to Revenue Ratio|P/S Multiple BNTX (biontech.de)|Abivax Corp (ABVX) - Price to Sales|ADMA Corp - P/S Multiple|Price-to-Sales Ratio PTGX|Immunovant Inc (IMVT) - Price-to-Revenue Ratio|KNSA - Price-to-Revenue Coefficient|GRFS (Grifols Biemat) - P/S Multiple|P/S Multiple Adaptive Biotechnologies Inc.|Price-to-Revenue Ratio Celldex Therapeutics (CLDX)|Price-to-Revenue Coefficient auriniapharma.com|Price-to-Revenue Ratio BioCryst Pharmaceuticals BCRX|Market Capitalization-to-Revenue Ratio VERA|Dianthus Pharma - P/S Multiple|PHVS - P/S Multiple|ABCL: P/S Multiple|TRML (Tourmaline Bio, Inc.) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Intrexon|PHAR - Price-to-Revenue Multiple|P/S Multiple NKTR|Price-to-Revenue Ratio UPB (Upstream Bio Corp)|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|Price-to-Revenue Coefficient immunome.com (IMNM)|Gossamer Bio Inc - P/S Multiple|Market Capitalization-to-Revenue Ratio KALV (KalVista Pharmaceuticals, Inc.)|SEPN: P/S Multiple|Market Cap to Revenue Pieris Pharmaceuticals Inc|Market Cap to Revenue SVRA|Market Cap to Revenue Rigel Pharmaceuticals (RIGL)|P/S Multiple ANAB|ATXS - Price to Sales|Price-to-Revenue Ratio enGene Corp ENGN|Price-to-Revenue Coefficient RAPT Therapeutics, Inc. (RAPT)|Aerovate - P/S Multiple|ACRS - P/S Multiple|KYTX (Kyverna Therapeutics) - Market Cap to Revenue|Price to Sales Tiziana Life Sciences Ltd. (TLSA)|Market Cap to Revenue CABA|Ventyx Biosciences (VTYX) - Price-to-Revenue Coefficient|P/S Multiple THTX|AVTX (Avalo Therapeutics, Inc) - Market Capitalization-to-Revenue Ratio|P/S Multiple ELDN (eledon.com)|AGEN - Market Cap to Revenue|CLYM - Price-to-Revenue Ratio|Price-to-Sales Ratio ZURA|ATYR: P/S Multiple|Adagene Corp (ADAG) - P/S Multiple|Market Cap to Revenue IMA|Shattuck Labs, Inc. - Price-to-Sales Ratio|Price-to-Revenue Ratio Equillium Inc (EQ)|P/S Multiple Connect Biopharma Holdings (CNTB)|Price-to-Revenue Ratio Immunic, Inc. IMUX|P/S Multiple Atara Biotherapeutics ATRA|IFRX - Price-to-Revenue Ratio|XFOR: Price-to-Revenue Ratio|ACET: P/S Multiple|CELU - Price-to-Revenue Coefficient|Price-to-Revenue Ratio inmunebio.com|Market Cap to Revenue Ratio BRNS (barinthusbio.com)|P/S Multiple KZR|P/S Multiple SAB Biotherapeutics, Inc (SABS)|P/S Multiple AKTX (Akari Therapeutics, Plc)|P/S Multiple enlivex.com ENLV|QTTB: Market Cap to Revenue|GOVX - P/S Multiple|Edesa Biotech Inc (EDSA) - Price-to-Revenue Ratio|IBIO - Price-to-Revenue Coefficient|Price-to-Revenue Ratio carismatx.com|XTLB: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Bolt Biotherapeutics Inc. (BOLT)|HCW Biologics - Market Cap to Revenue Ratio|Price-to-Revenue Ratio aptevotherapeutics.com APVO|AIM - Market Cap to Revenue|Aditxt - P/S Multiple|Price-to-Revenue Coefficient GRI Bio Corporation GRI|HIND (Vyome Holdings Inc.) - Market Cap to Revenue|revbiosciences.com (REVB) - P/S Multiple|INDP (Indaptus Corp) - P/S Multiple|Market Cap to Revenue Scinai Immunotherapeutics Ltd (SCNI)|Price-to-Revenue Ratio CalciMedica Inc (CALI)|AFMD (Affimed NV) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos Inc.)|P/S Multiple HOOKIPA HOOK|IGMS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ITOS (iTeos)|OCEA: P/S Multiple|TCBP (TC BioPharm Ltd) - Price-to-Revenue Ratio|THRD (Third Harmonic Bio Inc) - P/S Multiple